The blockade of B7-H1 and B7-H4 by using monoclonal antibodies may be applied for therapeutic use, as Thompson et al.,[34] indicated in their preliminary experiment using murine RCC models. This evidence concerns the gene VTCN1 and renal cell carcinoma.